[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"reliability-and-validity\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:reliability-and-validity":70},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,102,132,170,193,221,254],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":73,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":101},"100641475","qaiax-aihealth4u---ai-public-health-central-microcity-a-re-quantum-ai-agency-aka-ai-city-hall-project-upsto-app-nos-64074526-64063557-63903181-63729428-100641475",false,"NCT07661823","QAIAx (AIhealth4U) - AI Public Health Central: Microcity-A (re Quantum AI Agency Aka AI City Hall Project, UPSTO App Nos. 64\u002F074,526, 64\u002F063,557, 63\u002F903,181, 63\u002F729,428","QAIAx (AIhealth4U) - AI Public Health Central: Microcity-A (re Quantum AI Agency Aka AI City Hall Project, UPSTO App Nos. 64\u002F074,526, 64\u002F063,557, 63\u002F903,181, 63\u002F729,428: A Quantum AI Public Health Agency That Provides Free Public Health Services to Registered and Sponsored Visitors\u002FOccupants for RDT&E Under 28 U.S. Code 1498 (Classified as a PPA Under 10 U.S. Code 129a)","QAIAx","Inclusion Criteria:\n\n* Individuals aged 17 to 99 years old.\n* Referral by a licensed health services professional (e.g., R.N., N.P., Ph.D., M.D.).\n* Referral by a non-profit organization (e.g., 501c3, university, church).\n* Referral by a public agency (e.g., case manager, social worker, parole\u002Fprobation\u002FPTS officer, judge).\n\nExclusion Criteria:\n\n\\* Individuals under 17 or over 99 years of age.",true,"ALL","17 Years","99 Years",{"count":22,"type":23},1000000,"ESTIMATED","INTERVENTIONAL",[26],"NA","BRIEF SUMMARY\n\nA. \"What is the purpose of this study?\"\n\nThis study will test whether the \"AI City Hall Project\" (QAIAx), a quantum artificial intelligence (AI) public health agency, can provide free or low-cost behavioral and mental health services inside self-contained, dome-enclosed communities called \"Microcities\". Researchers want to see if AI-managed public administration, AI humanoid robots, holoportation of human-figures via 'holo-suites' (e.g., AI-119 Kikkeri Holo-Suit; AI-119 Vulcan QM-Ware) and advanced AI mental-health tools can lower housing and care costs, improve mental health outcomes (e.g., particular ecosystems using AI tools among persons with one or more addiction disorders), and be financially sustainable for people on fixed incomes or public assistance.\n\nB. \"What conditions does the study focus on?\"\n\nThe study focuses on adults with:\n\n* Autism spectrum disorders (Asperger's, autism, ADHD, ASD)\n* Substance use disorders (alcohol, opioids, marijuana, cocaine, MDMA\u002Fecstasy, tobacco\u002Fnicotine)\n* Psychiatric conditions (personality disorders, narcissism, gender dysphoria, eating disorders)\n* Behavioral addictions (gambling, sex addiction) and related issues (sex offence history).\n\nC. \"What does the study involve?\"\n\nEligible volunteers live in an omni AI-managed Microcity for up to 24 months. The community is housed in a geodesic dome that contains all daily necessities: housing, food, utilities, healthcare, and public services. Daily life is managed by an AI system (ISAC) and AI humanoid robots, with only occasional human oversight. Participants receive free mental-health treatment that may include AI-driven counselling, virtual-reality therapy (holo-suits), and non-invasive digital \"attitude inoculation\" protocols designed to reduce stress and addiction cravings. All participants also take AI-technology courses as a condition of enrolment. The study does not use any FDA-regulated drug, device, or biologic.\n\n\\*\\*Who can participate?\\*\\*\n\nYou may be able to join if you:\n\n* Are an adult (18 years or older)\n* Have a diagnosis of one of the listed mental-health or addiction disorders\n* Are referred by a licensed health professional (e.g., RN, NP, PhD, MD), a non-profit organisation (e.g., 501(c)(3), university, church), or a public agency (e.g., case manager, social worker, parole\u002Fprobation officer, judge)\n* Are willing to live in a closed, AI-managed community for up to one year and complete AI educational courses.\n\nParticipants who are veterans, receive public assistance (e.g., VA disability, SSDI\u002FSSI, Medicaid, Medicare), or are experiencing homelessness may be prioritised.\n\n\\*\\*Where is the study taking place?\\*\\* The study will be conducted at Microcity sites in the United States and internationally. The first administrative site is in Richmond, Virginia, USA. Additional sites are planned in partner nations, including tribal lands, military installations, and special economic zones.\n\n\\*\\*Who is sponsoring the study?\\*\\* The study is sponsored by \\*\\*Veterans Recovery Network Inc.\\*\\*, a non-profit organization, in collaboration with \\*\\*AI-119 Vulcan Project Research \\& Educational Technology Co. (PRETCO)\\*\\* and an AI legal agency. The study is conducted under U.S. federal research and development authorities (28 U.S.C. §1498; 10 U.S.C. §129a) and is part of a Cooperative Research and Development Agreement (CRADA) with U.S. Special Operations Command (USSOCOM).\n\nThis summary describes a planned clinical study. Not all details may be final. Information may change as the study progresses.",[29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72],"Asperger's Disorder","Asperger Disorder","Autism Disorder","Autism","ADHD - Attention Deficit Disorder With Hyperactivity","ADHD","ASD","Alcohol Abuse\u002FDependence","Alcohol Addiction","Alcohol and Other Drug Use Disorders","Alcohol and Other Substance Use Prevention","Gambling Addiction","Gambling Disorder","Sex Abuse","Sex Behavior","Sex Crimes","Sex Disorder","Sex Disorders","Gender Dysphoria, Adult","Eating Behavior Disorders","Narcotic-Related Disorders","Narcotic Addiction","Narcissism","Psychiatric Disorder","Psychedelic Effects in Healthy Volunteers","Psychedelic Experiences","Psychedelic Drug Dependence","Marijuana Use Disorder","Marijuana Abuse and Dependence","Smoking (Tobacco) Addiction","Smoking Among Youth","Smoking Abstinence","Abstinence, Sex","Opiate Substitution Treatment","Opioid Abuse (Disorder)","Opioid Abuse and Addiction","Cocaine Abuse","MDMA ('Ecstasy')","Addiction Disorders","Homeless and Low Incomes People, Refugees","Homelessness","Reliability and Validity","Anger Problems","Child Abuse, Sexual",[74,75,76,77,78,79,80,81,82,83,84,85,86,87,88],"ai city hall project","ai 119","ai119","qaia","qaiax","ai wat","veterans recovery network","veterans","addiction disorder","vulcan","artificial intelligence","agi","military","sex addiction","mental health treatment","NOT_YET_RECRUITING","2026-06-16",{"date":92,"type":93},"2026-06-22","ACTUAL",{"date":95,"type":23},"2026-08-01",{"date":97,"type":23},"2028-12-31",{"name":99,"class":100},"Veterans Recovery Network Inc.","OTHER",1,{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":17,"sex":109,"minAge":110,"maxAge":111,"enrollmentInfo":112,"targetDuration":4,"studyType":114,"phases":4,"briefSummary":115,"conditions":116,"keywords":119,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":101},"100625645","validity-and-reliability-of-the-two-minute-step-test-in-hemophilia-100625645","NCT07425327","Validity and Reliability of the Two-minute Step Test in Hemophilia","Investigating the Validity and Reliability of the Two-minute Step Test in Patients With Hemophilia","Inclusion Criteria:\n\n* Diagnosed with Hemophilia (A-B) by a physician,\n* Aged 6-18 years,\n* Receiving regular prophylactic treatment,\n* Inhibitor positive or negative,\n* No history of lower extremity joint bleeding within the last month,\n* Individuals who are willing to participate in the study,\n\nExclusion Criteria:\n\n* Patients who have undergone surgery on the lower extremities for any reason within the last 6 months,\n* Patients with neurological sequelae following a history of intracranial hemorrhage,\n* Patients experiencing cognitive impairment to the extent that they cannot understand the tests,\n* Patients who indicate they will be unable to participate in follow-up measurements.","MALE","6 Years","18 Years",{"count":113,"type":23},35,"OBSERVATIONAL","The aim of our study was to evaluate the psychometric properties of the 2-minute step test in hemophilia patients, assess its intra-rater and inter-rater reliability, and evaluate its convergent validity and construct validity supported by measurements of gait, balance, and functionality.",[117,118,70],"Hemophilia","Step",[120,121,122],"Hemophilia A","Hemophilia B","Two minute step test","2026-02-13",{"date":125,"type":93},"2026-02-20",{"date":127,"type":23},"2026-02-25",{"date":129,"type":23},"2026-06-25",{"name":131,"class":100},"Hasan Kalyoncu University",{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":17,"sex":18,"minAge":111,"maxAge":138,"enrollmentInfo":139,"targetDuration":4,"studyType":114,"phases":4,"briefSummary":141,"conditions":142,"keywords":150,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":101},"100625239","turkish-adaptation-of-the-cts-6-evaluation-tool-a-validation-and-reliability-study-100625239","NCT07420049","Turkish Adaptation of the CTS-6 Evaluation Tool: A Validation and Reliability Study","1\\) INCLUSION CRITERIA:\n\nParticipants aged 18-60 years will be categorized into three groups:\n\n1. Healthy Control Group\n2. Group Presenting with CTS-like Symptoms\n3. Group Diagnosed with CTS Based on Defined Criteria\n\na) Healthy Control Group: Participants in this group will have no clinical symptoms consistent with CTS based on specified clinical criteria and will be considered normal according to the defined electrophysiological criteria.\n\nb) Group Presenting with CTS-like Symptoms: Participants in this group may exhibit symptoms similar to clinically defined CTS; however, electrophysiological evaluations will show normal findings according to the defined criteria.\n\nb.1) Clinical Findings \u002F Symptoms:\n\nb.1.1) Symptoms:\n\n(A) Sensory symptoms in any of the 1st, 2nd, 3rd, or the radial part of the 4th finger\n\n(B) Symptoms alleviated by shaking, squeezing, or other hand movements\n\n(C) Pain or paresthesia associated with gripping or hand use\n\n(D) Nocturnal paresthesia causing awakening from sleep\n\nb.1.2) Diagnostic Tests \u002F Signs:\n\n1. Tinel Sign\n2. Phalen Test\n3. Reverse Phalen Test\n4. Carpal Tunnel Compression Test\n5. Flick Sign\n\n   A clinical diagnosis of CTS will require symptoms persisting for at least three months, with at least one of the B, C, or D symptoms in addition to symptom A, plus at least one positive diagnostic test or sign.\n\n   b.2) Electrophysiological Evaluation:\n\n   b.2.1) Mild CTS:\n\n   Median-to-ulnar sensory distal latency difference ≥ 0.4 ms at the 4th finger\n\n   Median nerve sensory distal latency ≥ 2.8 ms at the 2nd finger\n\n   Median nerve conduction velocity \\\u003C 50 m\u002Fs\n\n   Sensory nerve action potential ≥ 12 µV\n\n   b.2.2) Moderate CTS:\n\n   Median nerve distal motor latency at Abductor Pollicis Brevis (APB) 4 ms ≤ x \\\u003C 6.5 ms\n\n   Median nerve conduction velocity \\\u003C 50 m\u002Fs\n\n   Compound Muscle Action Potential (CMAP) ≥ 5 mV\n\n   b.2.3) Severe CTS:\n\n   Median nerve distal motor latency at APB ≥ 6.5 ms\n\n   Median nerve conduction velocity \\\u003C 50 m\u002Fs and\u002For CMAP \\\u003C 5 mV\n\n   c) Group Diagnosed with CTS Based on Defined Criteria: Participants in this group meet the clinical diagnostic criteria for CTS and additionally fulfill electrophysiological evaluation criteria for mild, moderate, or severe CTS.\n\n2\\) EXCLUSION CRITERIA:\n\n2.a) Participants Diagnosed with CTS Based on Defined Criteria:\n\nHistory of cardiac pacemaker\n\nHistory of lymphedema in the affected extremity\n\nHistory of cervical radiculopathy\n\nPresence of ipsilateral upper extremity tenosynovitis\n\nPresence of another compressive neuropathy in the ipsilateral upper extremity\n\nHistory of peripheral polyneuropathy\n\nPresence of metabolic disease\n\nHistory of fracture in the hand, wrist, or forearm\n\nCurrent pregnancy\n\nOpen wound on the wrist\n\nUncontrolled medical conditions (including endocrinological, cardiovascular, pulmonary, hematological, hepatic, renal, active systemic inflammatory disease, and\u002For malignancy)\n\nHistory of inflammatory rheumatologic or autoimmune disease\n\nAge \\\u003C18 years or \\>60 years\n\nTrauma to the wrist or median nerve within the last 3 months\n\nReceived any injection in the wrist\n\nUndergone any surgical procedure on the wrist\n\nMental or cognitive incapacity preventing understanding or completion of questionnaires\n\n2.b) Participants Presenting with CTS-like Symptoms:\n\nMental or cognitive incapacity preventing understanding or completion of questionnaires\n\nAge \\\u003C18 years or \\>60 years\n\nCTS diagnosis confirmed based on clinical and electrophysiological criteria\n\n2.c) Healthy Control Group Participants:\n\nMental or cognitive incapacity preventing understanding or completion of questionnaires\n\nAge \\\u003C18 years or \\>60 years\n\nPresence of any clinical symptoms potentially related to CTS based on defined clinical criteria\n\nElectrophysiological findings consistent with CTS","60 Years",{"count":140,"type":23},126,"The purpose of this study is to develop the Turkish version of the CTS-6 Evaluation Tool and to comprehensively assess its validity and reliability in the Turkish population. The CTS-6 Evaluation Tool is a widely used and reliable instrument for the assessment of diagnosis and symptom severity in patients with carpal tunnel syndrome.\n\nIn this study, the CTS-6 will undergo translation and cultural adaptation to ensure linguistic and cultural appropriateness for the Turkish population. The goal is to produce a valid, reliable, and practical tool that can be used efficiently in clinical settings. The adapted version is intended to be applicable across multiple medical specialties involved in the diagnosis and management of carpal tunnel syndrome in Turkey. The results are expected to provide a trustworthy Turkish version of the CTS-6 suitable for both clinical practice and research purposes.",[143,144,145,146,70,147,148,149],"Carpal Tunnel Syndrome (CTS)","Median Nerve Entrapment","Peripheral Nerve Disease","Peripheral Nerve Disorder","Cross-cultural Adaptation","TURKISH VALIDITY AND RELIABILITY STUDY OF CTS-6 EVALUATİON TOOL","Diagnostic Tool",[151,152,153,154,155,156,149,157,158,159,160],"CTS-6 Evaluation Tool","CTS-6","Cross-cultural adaptation","Carpal Tunnel Syndrome","median nerve entrapment","reliability and validity","Peripheral nerve disease","Peripheral nerve disorders","Turkish version","Turkish Validity and Reliability Study of CTS-6 Evaluation Tool","2026-02-12",{"date":163,"type":93},"2026-02-19",{"date":165,"type":23},"2026-03-01",{"date":167,"type":23},"2026-07-01",{"name":169,"class":100},"Istanbul University",{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":174,"acronym":4,"eligibilityCriteria":175,"healthyVolunteers":11,"sex":18,"minAge":4,"maxAge":111,"enrollmentInfo":176,"targetDuration":4,"studyType":114,"phases":4,"briefSummary":178,"conditions":179,"keywords":182,"overallStatus":183,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":101},"100613503","turkish-translation--validity-and-reliability-of-the-hypertonia-assessment-tool-in-children-with-motor-disorders-100613503","NCT07267442","Turkish Translation , Validity and Reliability of the Hypertonia Assessment Tool in Children With Motor Disorders","Inclusion Criteria:\n\n* as voluntary participation in the study,\n* a diagnosis of a neuromotor disorder under the age of 18,\n* sufficient cognitive ability to follow verbal commands\n\nExclusion Criteria:\n\n* Patients with any other systemic disease,\n* Who had received botulinum toxin A injections or undergone surgery within the past three months,\n* Be unable to follow verbal instructions\n* Medical treatment had been modified within the last month",{"count":177,"type":23},70,"Translating batteries with good psychometric properties into Turkish will increase the number of assessment batteries we can use in our language for clinical and academic studies. Therefore, the aim of our study was to verify the validity, reliability, and translation into Turkish of the Hypertonus Assessment Tool for children with motor disorders.",[180,70,181],"Motor Disorder","Hypertonia",[181,180,70],"RECRUITING","2025-12-04",{"date":186,"type":93},"2025-12-05",{"date":188,"type":93},"2025-01-10",{"date":190,"type":23},"2026-06-10",{"name":192,"class":100},"Kastamonu University",{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":17,"sex":18,"minAge":111,"maxAge":200,"enrollmentInfo":201,"targetDuration":4,"studyType":114,"phases":4,"briefSummary":203,"conditions":204,"keywords":208,"overallStatus":183,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":217,"leadSponsor":219,"locationsCount":101},"100592543","validity-and-reliability-of-gait-and-jump-parameters-measured-by-the-isen-device-in-healthy-adults-100592543","NCT06994793","Validity and Reliability of Gait and Jump Parameters Measured by the iSen Device in Healthy Adults","Investigation of the Validity and Reliability of Gait and Jumping Parameters Measured With iSen Device in Healthy Adults","Inclusion Criteria:\n\n* Age between 18 and 35 years. Voluntarily agree to participate in the study. No history of surgery in the lower extremities.\n\nExclusion Criteria:\n\n* Any musculoskeletal, neurological, or systemic pathology that could affect gait or jumping performance.\n\nInability to comply with study procedures.","35 Years",{"count":202,"type":23},60,"This study aims to evaluate the validity and reliability of gait and jumping parameters measured with the iSen device in healthy adults. Gait analysis is a valuable tool for assessing general health, cognitive performance, quality of life, and mortality. It is commonly used by clinicians to assess functional limitations resulting from neurological or orthopedic conditions and to guide treatment plans. Traditional gait assessments primarily focus on walking speed, but additional parameters such as step length, step time, and gait symmetry are crucial for a comprehensive analysis.\n\nThe study will also assess vertical jump performance, which is a surrogate measure of explosive lower limb strength and is commonly used in sports performance and injury prediction. The iSen device, a wearable and affordable sensor, will be compared to the validated BTS G-Walk system to evaluate the accuracy and consistency of its measurements. Participants aged 18-35 with no history of musculoskeletal, neurological, or systemic conditions will be included.\n\nThe study will be conducted at Gazi University and Kırıkkale University, where participants will undergo assessments of gait and jump performance using both iSen and BTS G-Walk devices. A test-retest reliability protocol will be employed with a seven-day interval between measurements. The results will provide evidence on the suitability of the iSen device for reliable and valid gait and jump measurements in clinical settings",[205,206,207,70],"Healthy Adults","Gait Analysis","Jumping Performance",[206,207,209,210,211,212],"iSen Device","Wearable Sensors","Reliability","Validity","2025-08-28",{"date":215,"type":93},"2025-08-29",{"date":188,"type":93},{"date":218,"type":23},"2026-02-01",{"name":220,"class":100},"Kırıkkale University",{"id":222,"slug":223,"hasResults":11,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":4,"eligibilityCriteria":227,"healthyVolunteers":17,"sex":18,"minAge":228,"maxAge":200,"enrollmentInfo":229,"targetDuration":4,"studyType":24,"phases":231,"briefSummary":232,"conditions":233,"keywords":238,"overallStatus":183,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":101},"100594828","perceptual-evaluation-and-rehabilitation-system-development-for-congenital-hearing-loss-100594828","NCT07024524","Perceptual Evaluation and Rehabilitation System Development for Congenital Hearing Loss","Development and Application of A Multimodal Perceptual Evaluation and Precision Rehabilitation System in Congenital Deafness","Inclusion Criteria:\n\nFor Congenital Deafness Group: Patients with congenital hearing loss with hearing thresholds ≥65 dB who have received hearing aids, cochlear implantation, or gene therapy; Age between 1 and 35 years old, regardless of gender.\n\nFor Healthy Controls Group: Participants with normal hearing thresholds (≤20 dB) whose age and gender matched to the patient group.\n\nMandarin Chinese as the native language. Participants and\u002For their guardians must provide informed consent before the trial, voluntarily sign a written consent form, and commit to receive evaluation at specified time points.\n\nCapable of effective communication with researchers under the guardian's assistance and willing to cooperate and comply with the researchers' requirements.\n\nParticipants and\u002For their guardians should have a correct understanding of the trial and appropriate expectations regarding potential benefits.\n\nExclusion Criteria:\n\nPresence of other otological disorders that may interfere with the surgical outcome or interpretation of study endpoints, such as otitis media, Meniere's disease, etc.\n\nPresence of other severe congenital diseases, such as congenital heart disease. Presence of severe systemic diseases or in the acute onset of diseases, such as pulmonary tuberculosis, active hepatitis B or C infection, active herpes zoster infection, pancreatitis, renal insufficiency, etc.\n\nIndividuals with low immunity, a history of immune deficiency or organ transplantation.\n\nIndividuals with a history of neurological, mental disorders, or moderate-to-severe cognitive dysfunction, such as epilepsy, dementia, autism spectrum disorders, etc.\n\nAny other conditions for which the investigators consider the subject unsuitable for participation in this clinical study.","1 Year",{"count":230,"type":23},210,[26],"This study aims to establish a novel multimodal evaluation and precision rehabilitation system for patients with congenital hearing loss who have received hearing aids, cochlear implantation, or emerging gene therapy. The proposed system will integrate age-stratified difficulty levels, combined with a gamified interaction platform or software designed to assess and train three core perceptual domains: auditory speech perception, music perception, and spatial hearing capabilities.",[234,235,236,237,70],"Congenital Hearing Loss","Gene Therapy","Speech Perception","Rehabilitation",[239,240,241,242,243,244,237],"Congenital hearing loss","Gene therapy","Multimodal assessment","Auditory speech perception","Music perception","Spatial hearing","2025-07-24",{"date":247,"type":93},"2025-07-28",{"date":249,"type":93},"2025-07-04",{"date":251,"type":23},"2028-05-05",{"name":253,"class":100},"Eye & ENT Hospital of Fudan University",{"id":255,"slug":256,"hasResults":11,"nctId":257,"briefTitle":258,"officialTitle":259,"acronym":4,"eligibilityCriteria":260,"healthyVolunteers":17,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":261,"targetDuration":4,"studyType":114,"phases":4,"briefSummary":262,"conditions":263,"keywords":267,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":101},"100585910","adaptation-of-the-intensive-care-unit-specific-pressure-injury-risk-scale-to-turkish-raps-icu-100585910","NCT06908512","Adaptation of the Intensive Care Unit-specific Pressure Injury Risk Scale to Turkish (RAPS-ICU)","Turkish Adaptation, Validity and Reliability of the Intensive Care Unit-specific Pressure Injury Risk Assessment Scale","Inclusion Criteria:\n\n* 18 years of age or older,\n* Staying in the Intensive Care Unit for at least 1 day,\n* Agreeing to participate in the study by themselves or a family member.\n* Volunteering to participate in the research\n* Full orientation and no psychiatric problems\n\nExclusion Criteria:\n\n\\- Having communication problems",{"count":202,"type":23},"The aim of this study was to evaluate the translation, cross-cultural fit, and psychometric properties of the ICU-specific pressure injury risk scale",[264,70,265,266],"Pressure Injury","Intensive Care Units (ICUs)","Assessment Scale",[264,70,268,266],"Intensive Care Units","2025-03-26",{"date":271,"type":93},"2025-04-03",{"date":273,"type":23},"2025-03-30",{"date":275,"type":23},"2025-11-12",{"name":277,"class":100},"Harran University"]